Balchem (BCPC) 10-Q 30 Apr 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2021	Apr. 22, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	1-13648
Entity Registrant Name	Balchem Corporation
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	13-2578432
Entity Address, Address Line One	52 Sunrise Park Road
Entity Address, City or Town	New Hampton
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10958
City Area Code	845
Local Phone Number	326-5600
Title of 12(b) Security	Common Stock, par value $.06-2/3 per share
Trading Symbol	BCPC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,435,692
Entity Central Index Key	0000009326
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 88,535	$ 84,571
Accounts receivable, net of allowance for doubtful accounts of $2,158 and $2,092 at March 31, 2021 and December 31, 2020 respectively	106,806	98,214
Inventories	77,022	70,620
Prepaid expenses	4,995	6,598
Prepaid income taxes	0	3,447
Other current assets	3,846	3,438
Total current assets	281,204	266,888
Property, plant and equipment, net	226,513	228,096
Goodwill	526,246	529,463
Intangible assets with finite lives, net	113,659	121,660
Right of use assets	8,708	8,410
Other assets	12,885	11,326
Total assets	1,169,215	1,165,843
Current liabilities:
Trade accounts payable	33,765	23,742
Accrued expenses	37,400	29,655
Accrued compensation and other benefits	11,474	19,753
Dividends payable	203	18,941
Income taxes payable	3,639	0
Lease liabilities - current	2,282	2,337
Total current liabilities	88,763	94,428
Revolving loan	153,569	163,569
Deferred income taxes	51,865	51,359
Lease liabilities - non-current	6,423	6,079
Derivative liabilities	6,758	11,658
Other long-term obligations	12,345	10,517
Total liabilities	319,723	337,610
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,471,019 shares issued and 32,451,930 shares outstanding at March 31, 2021 and 32,448,705 shares issued and 32,372,621 outstanding at December 31, 2020, respectively	2,165	2,164
Additional paid-in capital	170,837	173,029
Retained earnings	680,151	656,740
Accumulated other comprehensive (loss) income	(1,451)	4,173
Treasury stock, at cost: 19,089 and 76,084 shares at March 31, 2021 and December 31, 2020, respectively	(2,210)	(7,873)
Total stockholders' equity	849,492	828,233
Total liabilities and stockholders' equity	$ 1,169,215	$ 1,165,843

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Allowance for doubtful accounts	$ 2,158	$ 2,092
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,471,019	32,448,705
Common stock, shares outstanding (in shares)	32,451,930	32,372,621
Treasury stock (in shares)	19,089	76,084

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Net sales	$ 185,656	$ 174,436
Cost of sales	126,929	119,105
Gross margin	58,727	55,331
Operating expenses:
Selling expenses	14,924	15,430
Research and development expenses	2,749	2,700
General and administrative expenses	10,479	10,923
Total operating expenses	28,152	29,053
Earnings from operations	30,575	26,278
Other expenses:
Interest expense, net	725	1,696
Other (income) expense, net	(133)	92
Total other expenses (income)	592	1,788
Earnings before income tax expense	29,983	24,490
Income tax expense	6,572	4,722
Net earnings	$ 23,411	$ 19,768
Net earnings per common share - basic (in dollars per share)	$ 0.73	$ 0.62
Net earnings per common share - diluted (in dollars per share)	$ 0.72	$ 0.61

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net earnings	$ 23,411	$ 19,768
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(6,143)	781
Unrealized gain (loss) on cash flow hedge	512	(3,107)
Change in postretirement benefit plans	7	(579)
Other comprehensive loss	(5,624)	(2,905)
Comprehensive income	$ 17,787	$ 16,863

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Treasury Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2019	$ 743,667	$ 590,921	$ (5,564)	$ 2,161	$ (18,069)	$ 174,218
Beginning balance, common stock (in shares) at Dec. 31, 2019				32,405,796
Beginning balance, treasury stock (in shares) at Dec. 31, 2019					(203,879)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	19,768	19,768
Other comprehensive (loss) income	(2,905)		(2,905)
Treasury shares purchased	(891)				$ (891)
Treasury shares purchased (in shares)					(8,224)
Shares and options issued under stock plans	6,632			$ 3	$ 7,266	(637)
Shares and options issued under stock plans (in shares)				41,619	81,530
Ending balance at Mar. 31, 2020	766,271	610,689	(8,469)	$ 2,164	$ (11,694)	173,581
Ending balance, common stock (in shares) at Mar. 31, 2020				32,447,415
Ending balance, treasury stock (in shares) at Mar. 31, 2020					(130,573)
Beginning balance at Dec. 31, 2020	828,233	656,740	4,173	$ 2,164	$ (7,873)	173,029
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,448,705
Beginning balance, treasury stock (in shares) at Dec. 31, 2020					(76,084)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	23,411	23,411
Other comprehensive (loss) income	(5,624)		(5,624)
Treasury shares purchased	(1,596)				$ (1,596)
Treasury shares purchased (in shares)					(13,475)
Shares and options issued under stock plans	5,068			$ 1	$ 7,259	(2,192)
Shares and options issued under stock plans (in shares)				22,314	70,470
Ending balance at Mar. 31, 2021	$ 849,492	$ 680,151	$ (1,451)	$ 2,165	$ (2,210)	$ 170,837
Ending balance, common stock (in shares) at Mar. 31, 2021				32,471,019
Ending balance, treasury stock (in shares) at Mar. 31, 2021					(19,089)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings	$ 23,411	$ 19,768
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	12,364	12,549
Stock compensation expense	2,622	2,181
Deferred income taxes	0	135
Provision for doubtful accounts	69	522
Unrealized gain on foreign currency transactions and deferred compensation	(230)	(23)
Changes in assets and liabilities
Accounts receivable	(9,610)	(13,516)
Inventories	(6,702)	528
Prepaid expenses and other current assets	1,000	(349)
Accounts payable and accrued expenses	10,344	(3,098)
Income taxes	7,043	4,523
Other	296	(655)
Net cash provided by operating activities	40,607	22,565
Cash flows from investing activities:
Capital expenditures and intangible assets acquired	(6,312)	(5,394)
Proceeds from sale of assets	86	0
Net cash used in investing activities	(6,226)	(5,394)
Cash flows from financing activities:
Proceeds from revolving loan	5,000	10,000
Principal payments on revolving loan	(15,000)	(5,000)
Principal payments on finance lease	(39)	0
Proceeds from stock options exercised	2,402	4,435
Dividends paid	(18,700)	(16,704)
Purchase of treasury stock	(1,596)	(891)
Net cash used in financing activities	(27,933)	(8,160)
Effect of exchange rate changes on cash	(2,484)	(724)
Increase in cash and cash equivalents	3,964	8,287
Cash and cash equivalents beginning of period	84,571	65,672
Cash and cash equivalents end of period	$ 88,535	$ 73,959

CONDENSED CONSOLIDATED FINANCIA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The condensed consolidated financial statements presented herein have been prepared in accordance with the accounting policies described in its December 31, 2020 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2020. The condensed consolidated financial statements reflect the operations of Balchem Corporation and its subsidiaries (the "Company"). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the operating results expected for the full year or any interim period. Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this standards update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued Accounting Standards Update ("ASU") 2021-01, "Reference Rate Reform (Topic 848): Scope." This ASU clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company is currently evaluating the impact of this pronouncement on the consolidated financial statements and disclosures. Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." The amendments in this Update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new standard on January 1, 2021. The standard did not have a significant impact on the Company's consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company's consolidated financial statements and disclosures. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The Company adopted the new standard and related updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY STOCK-BASED COMPENSATION The Company’s results for the three months ended March 31, 2021 and 2020 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Three Months Ended March 31, 2021 2020 Cost of sales $ 299 $ 266 Operating expenses 2,323 1,915 Net earnings (2,022) (1,663) As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest. The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of March 31, 2021, the plans had 688,727 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, three three Option activity for the three months ended March 31, 2021 and 2020 is summarized below: For the three months ended Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.11 Exercised (34) 70.53 Forfeited (2) 101.38 Canceled (1) 74.57 Outstanding as of March 31, 2021 950 $ 86.11 $ 37,322 7.0 Exercisable as of March 31, 2021 604 $ 73.11 $ 31,603 5.8 For the three months ended Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2019 951 $ 68.18 $ 31,814 Granted 145 111.94 Exercised (82) 54.39 Forfeited (4) 89.90 Canceled — — Outstanding as of March 31, 2020 1,010 $ 75.48 $ 25,399 6.7 Exercisable as of March 31, 2020 664 $ 65.39 $ 22,131 5.4 ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 33% and 26%; risk-free interest rates of 0.5% and 1.4%; and expected lives of 4.9 years and 3.7 years, in each case for the three months ended March 31, 2021 and 2020, respectively. The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life. Other information pertaining to option activity during the three months ended March 31, 2021 and 2020 was as follows: Three Months Ended 2021 2020 Weighted-average fair value of options granted $ 33.10 $ 23.05 Total intrinsic value of stock options exercised ($000s) $ 1,917 $ 4,019 Non-vested restricted stock activity for the three months ended March 31, 2021 and 2020 is summarized below: Three Months Ended March 31, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 159 $ 90.71 138 $ 80.03 Granted 36 119.11 34 111.44 Vested (10) 85.37 (20) 67.43 Forfeited (2) 86.69 (1) 86.82 Non-vested balance as of March 31 183 $ 96.70 151 $ 89.21 Non-vested performance share activity for the three months ended March 31, 2021 and 2020 is summarized below: Three Months Ended March 31, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 71 $ 91.99 70 $ 81.26 Granted 36 108.74 20 126.46 Vested (24) 70.64 (8) 104.15 Forfeited (11) 74.57 (11) 82.71 Non-vested balance as of March 31 72 $ 110.22 71 $ 91.99 The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR), where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 0.2% and 1.4%; dividend yields of 0.6% and 0.5%; volatilities of 33% and 24%; and initial TSR’s of 11.7% and 10.9%, in each case for the three months ended March 31, 2021 and 2020, respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. As of March 31, 2021 and 2020, there was $23,009 and $19,308, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of March 31, 2021, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.9 years. The Company estimates that share-based compensation expense for the year ended December 31, 2021 will be approximately $11,400. REPURCHASE OF COMMON STOCK

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Raw materials $ 28,900 $ 24,536 Work in progress 3,822 3,050 Finished goods 44,300 43,034 Total inventories $ 77,022 $ 70,620

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at March 31, 2021 and December 31, 2020 are summarized as follows: March 31, 2021 December 31, 2020 Land $ 11,923 $ 12,215 Building 87,677 86,873 Equipment 248,326 247,884 Construction in progress 33,276 31,240 381,202 378,212 Less: accumulated depreciation 154,689 150,116 Property, plant and equipment, net $ 226,513 $ 228,096

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The Company had goodwill in the amount of $526,246 and $529,463 as of March 31, 2021 and December 31, 2020, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The decrease in goodwill is due to foreign exchange translation adjustments. Identifiable intangible assets with finite lives at March 31, 2021 and December 31, 2020 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at Gross Carrying Amount at Accumulated Amortization at Customer relationships & lists 10-20 $ 241,516 $ 161,772 $ 243,557 $ 158,051 Trademarks & trade names 2-17 43,154 26,084 43,208 24,974 Developed technology 5-12 20,318 13,991 21,674 13,693 Other 2-18 23,145 12,627 21,624 11,685 $ 328,133 $ 214,474 $ 330,063 $ 208,403

EQUITY-METHOD INVESTMENT

EQUITY-METHOD INVESTMENT	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company receives up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $144 and $138 for the three months ended March 31, 2021 and 2020, respectively, relating to its portion of the joint venture's expenses in other expense. During first quarter of 2021 and 2020, the Company made capital contributions to the investment totaling $13 and $667, res pectively. The carrying value of the joint venture at March 31, 2021 and December 31, 2020 is $4,840 and $4,971, respectively, and is recorded in other assets.

REVOLVING LOAN

REVOLVING LOAN	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
REVOLVING LOAN	REVOLVING LOAN On June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "Credit Agreement"), which replaced the existing credit facility that had provided for a senior secured term loan of $350,000 and a revolving loan of $100,000. The Credit Agreement, which expires on June 27, 2023, provides for revolving loans up to $500,000 (collectively referred to as the “loans”). The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The initial proceeds from the Credit Agreement were used to repay the outstanding balance of $210,750 on its senior secured term loan, which was due May 2019. As of March 31, 2021 a nd December 31, 2020, t he total balance outstanding on the Credit Agreement amounted to $153,569 and $163,569, respectively. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. Amounts outstanding under the Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the Credit Agreement, and the interest rate was 1.234% at March 31, 2021. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the Credit Agreement and ranges from 0.15% to 0.275% (0.150% at March 31, 2021). The unused portion of the revolving loan amounted to $346,431 at March 31, 2021. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders. Costs associated with the issuance of the revolving loans are capitalized and amortized on a straight-line basis over the term of the Credit Agreement, which is not materially different than the effective interest method. Costs associated with the issuance of the extinguished debt instrument were capitalized and amortized over the term of the respective financing arrangement using the effective interest method. Capitalized costs net of accumulated amortization totaled $632 and $703 at March 31, 2021 and December 31, 2020, respectively, and are included in other assets on the condensed consolidated balance sheets. Amortization expense pertaining to these costs totaled $71 for both the three months ended March 31, 2021 and 2020, and are included in interest expense in the accompanying condensed consolidated statements of earnings. The Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At March 31, 2021, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements are secured by assets of the Company.

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
NET EARNINGS PER SHARE	NET EARNINGS PER SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended 2021 2020 Net Earnings - Basic and Diluted $ 23,411 $ 19,768 Shares (000s) Weighted Average Common Shares - Basic 32,255 32,135 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 402 382 Weighted Average Common Shares - Diluted 32,657 32,517 Net Earnings Per Share - Basic $ 0.73 $ 0.62 Net Earnings Per Share - Diluted $ 0.72 $ 0.61 The number of anti-dilutive shares were 311,030 and 212,551 for the three months ended March 31, 2021 and 2020, respectively. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended March 31, 2021 and 2020, was 21.9% and 19.3%, respectively. The increase in the effective tax rate for the three months ended March 31, 2021 compared to the three months ended March 31, 2020 was primarily due to a reduction in certain tax credits and higher enacted tax rates in several states within the United States. On March 27, 2020, Congress passed the Coronavirus Aid, Relief, and Economic Security Act, and on December 27, 2020, Congress passed an additional round of COVID relief legislation as part of the Bipartisan-Bicameral Omnibus COVID Relief Deal. The Company has reviewed the change in law and determined that it does not have a significant impact on the Company’s tax provision or financial statements. In addition, Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the SEC, and/or the Financial Accounting Standards Board ("FASB") regarding this act. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations, and the expected timing of the reversals of existing temporary differences. The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of March 31, 2021, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2016. As of March 31, 2021 and December 31, 2020, the Company had approximately $5,400 and $5,335, respectively, of unrecognized tax benefits, which are included in other long-term obligations on the Company’s condensed consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the condensed consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at March 31, 2021 and December 31, 2020 was approximately $1,908 and $1,845, respectively, and is included in other long-term obligations.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated." Human Nutrition & Health The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technology has been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. When combined with its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, as well as ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Animal Nutrition & Health The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production, delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products Ethylene oxide, at the 100% level and blended with carbon dioxide, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. The Company’s 100% ethylene oxide product and blends are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. Contract sterilizers and medical device manufacturers are principal customers for this product. The Company also sells single use canisters with 100% ethylene oxide for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials. The Company also distributes a number of other gases for various uses, most notably propylene oxide and ammonia. Propylene oxide is marketed and sold in the U.S. as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product in the U.S. primarily in recyclable, single-walled, carbon steel cylinders according to standards outlined by the Environmental Protection Agency ("EPA") and the Department of Transportation ("DOT"). Propylene oxide is also sold worldwide to customers in approved reusable and recyclable drum and cylinder packaging for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings. Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder drum and cylinder packaging approved for use in the countries these products are shipped to. The Company's inventory of cylinders for these products also represents a significant capital investment. The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily into high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate ® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. The segment information is summarized as follows: Business Segment Assets March 31, December 31, Human Nutrition & Health $ 727,869 $ 717,232 Animal Nutrition & Health 151,773 157,454 Specialty Products 182,092 190,449 Other and Unallocated (1) 107,481 100,708 Total $ 1,169,215 $ 1,165,843 Business Segment Net Sales Three Months Ended 2021 2020 Human Nutrition & Health $ 104,516 $ 95,508 Animal Nutrition & Health 51,148 48,641 Specialty Products 28,008 27,996 Other and Unallocated (2) 1,984 2,291 Total $ 185,656 $ 174,436 Business Segment Earnings Before Income Taxes Three Months Ended 2021 2020 Human Nutrition & Health $ 19,690 $ 12,135 Animal Nutrition & Health 5,056 8,044 Specialty Products 7,189 7,986 Other and Unallocated (2) (1,360) (1,887) Interest and other expense (592) (1,788) Total $ 29,983 $ 24,490 Depreciation/Amortization Three Months Ended 2021 2020 Human Nutrition & Health $ 7,573 $ 7,844 Animal Nutrition & Health 1,764 1,755 Specialty Products 2,269 2,392 Other and Unallocated (2) 758 558 Total $ 12,364 $ 12,549 Capital Expenditures Three Months Ended 2021 2020 Human Nutrition & Health $ 3,967 $ 3,507 Animal Nutrition & Health 1,631 1,092 Specialty Products 330 382 Other and Unallocated (2) 23 8 Total $ 5,951 $ 4,989 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $234 and $1,272 for the first quarter of 2021 and 2020, respectively, and (ii) Unallocated amortization expense of $675 and $472 for the first quarter of 2021 and 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings.

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods. The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended 2021 2020 Product Sales $ 175,988 $ 167,565 Co-manufacturing 7,278 5,241 Consignment 1,051 619 Product Sales Revenue 184,317 173,425 Royalty Revenue 1,339 1,011 Total Revenue $ 185,656 $ 174,436 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended 2021 2020 United States $ 137,851 $ 126,909 Foreign Countries 47,805 47,527 Total Revenue $ 185,656 $ 174,436 Product Sales Revenues The Company’s primary operation is the manufacturing and sale of health and nutrition ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of four sub-streams: product sales, co-manufacturing, bill and hold, and consignment. Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials. The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer. Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided. Royalty Revenues Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment. Contract Liabilities The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable. The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for products shipped.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the three months ended March 31, 2021 and 2020 for income taxes and interest is as follows: Three Months Ended 2021 2020 Income taxes $ 2 $ 8 Interest $ 1,363 $ 1,619

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	3 Months Ended
	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The changes in accumulated other comprehensive income/(loss) were as follows: Three Months Ended 2021 2020 Net foreign currency translation adjustment $ (6,143) $ 781 Net change of cash flow hedge (see Note 19 for further information) Unrealized gain (loss) on cash flow hedge 677 (3,933) Tax (165) 826 Net of tax 512 (3,107) Net change in postretirement benefit plan (see Note 14 for further information) Amortization of prior service cost 18 19 Amortization of gain (5) (13) Prior service credit (4) — Total before tax 9 6 Tax (2) (1) Adjustment (1) — (584) Net of tax and adjustment 7 (579) Total other comprehensive loss $ (5,624) $ (2,905) (1) One-time adjustment to the postretirement account. Included in "Net foreign currency translation adjustment" were gains of $3,197 and $4,419, related to a net investment hedge, which were net of taxes of $1,026 and $1,174 for the three months ended March 31, 2021 and 2020, respectively. See Note 19, "Derivative Instruments and Hedging Activities." Accumulated other comprehensive income (loss) at March 31, 2021 and December 31, 2020 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2020 $ 7,653 $ (3,684) $ 204 $ 4,173 Other comprehensive (loss) income (6,143) 512 7 (5,624) Balance March 31, 2021 $ 1,510 $ (3,172) $ 211 $ (1,451)

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	3 Months Ended
	Mar. 31, 2021
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Defined Contribution Plans The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1st, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. Postretirement Medical Plans The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement. Net periodic benefit costs for such retirement medical plans were as follows: Three Months Ended 2021 2020 Service cost $ 22 $ 17 Interest cost 6 6 Amortization of prior service cost 18 19 Amortization of gain (6) (13) Net periodic benefit cost $ 40 $ 29 The amount recorded for these obligations on the Company’s balance sheets as of March 31, 2021 and December 31, 2020 were $1,402 and $1,374, respectively, and are included in other long-term obligations. These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plans have typically been less than $100 per year. Defined Benefit Pension Plans On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amount recorded for these obligations on the Company's consolidated balance sheet as of March 31, 2021 and December 31, 2020 were $920 and $950, respectively, and were included in other long-term obligations. Net periodic benefit costs for such benefit pension plans were as follows: Three Months Ended 2021 2020 Service cost with interest to end of year $ 17 $ 26 Interest cost 4 5 Expected return on plan assets (9) (4) Amortization of gain 1 — Total net periodic benefit cost $ 13 $ 27 Deferred Compensation Plan

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at March 31, 2021 are as follows: Year April 1, 2021 to December 31, 2021 $ 2,498 2022 2,557 2023 2,045 2024 1,238 2025 639 2026 443 Thereafter 2,241 Total minimum lease payments $ 11,661 The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the facility for potential liabilities associated with the Superfund site. In September 2020, BCP Ingredients, Inc. ("BCP"), the Company subsidiary that operates the site, received a General Notice Letter from the EPA regarding BCP's potential liability for 1,4 dioxane contamination at the site. BCP currently believes that the 1,4 dioxane contamination is associated with the former owner’s operations and has engaged experts to study site conditions and hydrogeology in connection with preparing its response to the notice. From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at March 31, 2021 and December 31, 2020 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at March 31, 2021 and December 31, 2020 includes $813 and $817 in money market funds, respectively. Non-current assets at March 31, 2021 and December 31, 2020 includes $5,319 and $3,581, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.” The Company also has derivative financial instruments, consisting of a cross-currency swap and an interest rate swap, which are included in derivative assets or derivative liabilities, in the consolidated balance sheets (see Note 19, "Derivative Instruments and Hedging Activities"). The fair values of these derivative instruments are determined based on Level 2 inputs, using significant inputs that are observable either directly or indirectly, including interest rate curves and implied volatilities. The derivative liability related to the cross-currency swap was $2,570 and $6,793 at March 31, 2021 and December 31, 2020, respectively. The derivative liability related to the interest rate swap was $4,188 and $4,865 at March 31, 2021 and December 31, 2020, respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the consolidated statements of earnings. Payments for the services the Company provided amounted to $827 and $853 for the three months ended March 31, 2021 and 2020, respectively. The raw materials purchased and subsequently sold amounted to $5,462 and $4,711 for the three months ended March 31, 2021 and 2020, respectively. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $4,391 and $3,721 for the three months ended March 31, 2021 and 2020, respectively. At March 31, 2021 and December 31, 2020, the Company had receivables of $3,794 and $2,809, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold and payables of $2,569 and $2,239, respectively, for finished goods received recorded in accounts payable. In addition, the Company had receivables in the amount of $97 and $72, respectively, related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of March 31, 2021 and December 31, 2020. The Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of March 31, 2021 and December 31, 2020.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from March 31, 2021. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At March 31, 2021 and December 31, 2020, the Company had finance lease liabilities of $2,592 and $2,631, respectively, which were recorded under lease liabilities (current and non-current) in the consolidated balance sheet. Right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 are summarized as follows: Right of use assets March 31, 2021 December 31, 2020 Operating leases $ 6,189 $ 5,838 Finance leases 2,519 2,572 Total $ 8,708 $ 8,410 Lease liabilities - current March 31, 2021 December 31, 2020 Operating leases $ 2,121 $ 2,178 Finance leases 161 159 Total $ 2,282 $ 2,337 Lease liabilities - non-current March 31, 2021 December 31, 2020 Operating leases $ 3,992 $ 3,607 Finance leases 2,431 2,472 Total $ 6,423 $ 6,079 For the three months ended March 31, 2021 and 2020, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the periods and amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended 2021 2020 Lease Cost Operating lease cost $ 716 $ 741 Finance Lease cost Amortization of ROU asset 52 — Interest on lease liabilities 33 — Total finance lease cost $ 85 $ — Total lease cost $ 801 $ 741 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 739 $ 744 Operating cash flows from finance leases 33 — Financing cash flows from finance leases 39 — $ 811 $ 744 ROU assets obtained in exchange for new operating lease liabilities, net of ROU assets disposals $ 1,036 $ 9 Weighted-average remaining lease term - operating leases 4.14 years 4.93 years Weighted-average remaining lease term - finance leases 12.00 years n/a Weighted-average discount rate - operating leases 4.2 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a
LEASES	LEASES The Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from March 31, 2021. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. The Company did not identify any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2021: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At March 31, 2021 and December 31, 2020, the Company had finance lease liabilities of $2,592 and $2,631, respectively, which were recorded under lease liabilities (current and non-current) in the consolidated balance sheet. Right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 are summarized as follows: Right of use assets March 31, 2021 December 31, 2020 Operating leases $ 6,189 $ 5,838 Finance leases 2,519 2,572 Total $ 8,708 $ 8,410 Lease liabilities - current March 31, 2021 December 31, 2020 Operating leases $ 2,121 $ 2,178 Finance leases 161 159 Total $ 2,282 $ 2,337 Lease liabilities - non-current March 31, 2021 December 31, 2020 Operating leases $ 3,992 $ 3,607 Finance leases 2,431 2,472 Total $ 6,423 $ 6,079 For the three months ended March 31, 2021 and 2020, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the periods and amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended 2021 2020 Lease Cost Operating lease cost $ 716 $ 741 Finance Lease cost Amortization of ROU asset 52 — Interest on lease liabilities 33 — Total finance lease cost $ 85 $ — Total lease cost $ 801 $ 741 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 739 $ 744 Operating cash flows from finance leases 33 — Financing cash flows from finance leases 39 — $ 811 $ 744 ROU assets obtained in exchange for new operating lease liabilities, net of ROU assets disposals $ 1,036 $ 9 Weighted-average remaining lease term - operating leases 4.14 years 4.93 years Weighted-average remaining lease term - finance leases 12.00 years n/a Weighted-average discount rate - operating leases 4.2 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with the JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap (net investment hedge) with the JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the Credit Agreement. The net interest expense related to the interest rate swap contract was $521 and $121 for the three months ended March 31, 2021 and 2020, which were recorded in the condensed consolidated statements of operations under interest expense, net. At the same time, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $556 and $563, respectively, for the three months ended March 31, 2021 and 2020, which were recorded in the condensed consolidated statements of operations under interest expense, net. The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net derivative asset or derivative liability on the consolidated balance sheets. As of March 31, 2021 and December 31, 2020, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative liabilities March 31, 2021 December 31, 2020 Interest rate swap $ 4,188 $ 4,865 Cross-currency swap 2,570 6,793 Derivative liabilities $ 6,758 $ 11,658 On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting. As of March 31, 2021, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income. Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three months ended March 31, 2021 and 2020: Location within Statements of Comprehensive Income Three Months Ended 2021 2020 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 512 $ (3,107) Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment 3,197 4,419 Total $ 3,709 $ 1,312

CONDENSED CONSOLIDATED FINANC_2

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Issued Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this standards update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued Accounting Standards Update ("ASU") 2021-01, "Reference Rate Reform (Topic 848): Scope." This ASU clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company is currently evaluating the impact of this pronouncement on the consolidated financial statements and disclosures. Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update ("ASU") 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." The amendments in this Update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The effective date of this Update is for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted. The Standard may be adopted either using the prospective or retrospective transition approach and could also be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The Company adopted the new standard on January 1, 2021. The standard did not have a significant impact on the Company's consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract.” The guidance requires implementation costs incurred by customers in cloud computing arrangements to be deferred over the noncancelable term of the cloud computing arrangements plus any optional renewal periods (1) that are reasonably certain to be exercised by the customer or (2) for which exercise of the renewal option is controlled by the cloud service provider. The effective date of this pronouncement is for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The standard may be adopted either using the prospective or retrospective transition approach. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company’s consolidated financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, “Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans,” which modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of disclosures and adds disclosure requirements identified as relevant. This update should be applied on a retrospective basis to all periods presented and is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. The Company adopted the new standard on January 1, 2020. The standard update did not have a significant impact on the Company's consolidated financial statements and disclosures. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment” (ASU 2017-04), which addresses changes to the testing for goodwill impairment by eliminating Step 2 of the process. The guidance is effective for annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. The Company adopted the new standard on January 1, 2020. This ASU did not have a significant impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments", which requires that credit losses be reported based on expected losses instead of the incurred loss model. The update made several consequential amendments to the codification which requires the accounting for available-for-sale debt securities to be individually assessed for credit losses when fair value is less than the amortized cost basis. The FASB subsequently issued ASU 2019-04, ASU 2019-05, and ASU 2019-11, all of which further clarified ASU 2016-13. The Company adopted the new standard and related updates on January 1, 2020. The adoption did not have a significant impact on the consolidated financial statements.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost on Net Earnings	The Company’s results for the three months ended March 31, 2021 and 2020 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Three Months Ended March 31, 2021 2020 Cost of sales $ 299 $ 266 Operating expenses 2,323 1,915 Net earnings (2,022) (1,663)
Schedule of Stock Option Activity	Option activity for the three months ended March 31, 2021 and 2020 is summarized below: For the three months ended Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.11 Exercised (34) 70.53 Forfeited (2) 101.38 Canceled (1) 74.57 Outstanding as of March 31, 2021 950 $ 86.11 $ 37,322 7.0 Exercisable as of March 31, 2021 604 $ 73.11 $ 31,603 5.8 For the three months ended Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2019 951 $ 68.18 $ 31,814 Granted 145 111.94 Exercised (82) 54.39 Forfeited (4) 89.90 Canceled — — Outstanding as of March 31, 2020 1,010 $ 75.48 $ 25,399 6.7 Exercisable as of March 31, 2020 664 $ 65.39 $ 22,131 5.4
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to option activity during the three months ended March 31, 2021 and 2020 was as follows: Three Months Ended 2021 2020 Weighted-average fair value of options granted $ 33.10 $ 23.05 Total intrinsic value of stock options exercised ($000s) $ 1,917 $ 4,019
Schedule of Non-vested Restricted Stock Activity	Non-vested restricted stock activity for the three months ended March 31, 2021 and 2020 is summarized below: Three Months Ended March 31, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 159 $ 90.71 138 $ 80.03 Granted 36 119.11 34 111.44 Vested (10) 85.37 (20) 67.43 Forfeited (2) 86.69 (1) 86.82 Non-vested balance as of March 31 183 $ 96.70 151 $ 89.21
Schedule of Non-vested Performance Share Activity	Non-vested performance share activity for the three months ended March 31, 2021 and 2020 is summarized below: Three Months Ended March 31, 2021 2020 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 71 $ 91.99 70 $ 81.26 Granted 36 108.74 20 126.46 Vested (24) 70.64 (8) 104.15 Forfeited (11) 74.57 (11) 82.71 Non-vested balance as of March 31 72 $ 110.22 71 $ 91.99

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories at March 31, 2021 and December 31, 2020 consisted of the following: March 31, 2021 December 31, 2020 Raw materials $ 28,900 $ 24,536 Work in progress 3,822 3,050 Finished goods 44,300 43,034 Total inventories $ 77,022 $ 70,620

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment at March 31, 2021 and December 31, 2020 are summarized as follows: March 31, 2021 December 31, 2020 Land $ 11,923 $ 12,215 Building 87,677 86,873 Equipment 248,326 247,884 Construction in progress 33,276 31,240 381,202 378,212 Less: accumulated depreciation 154,689 150,116 Property, plant and equipment, net $ 226,513 $ 228,096

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets	Identifiable intangible assets with finite lives at March 31, 2021 and December 31, 2020 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at Gross Carrying Amount at Accumulated Amortization at Customer relationships & lists 10-20 $ 241,516 $ 161,772 $ 243,557 $ 158,051 Trademarks & trade names 2-17 43,154 26,084 43,208 24,974 Developed technology 5-12 20,318 13,991 21,674 13,693 Other 2-18 23,145 12,627 21,624 11,685 $ 328,133 $ 214,474 $ 330,063 $ 208,403

NET EARNINGS PER SHARE (Tables)

NET EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Reconciliation of the Net Earnings and Shares Used in Calculating Basic and Diluted Net Earnings Per Share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended 2021 2020 Net Earnings - Basic and Diluted $ 23,411 $ 19,768 Shares (000s) Weighted Average Common Shares - Basic 32,255 32,135 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 402 382 Weighted Average Common Shares - Diluted 32,657 32,517 Net Earnings Per Share - Basic $ 0.73 $ 0.62 Net Earnings Per Share - Diluted $ 0.72 $ 0.61

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The segment information is summarized as follows: Business Segment Assets March 31, December 31, Human Nutrition & Health $ 727,869 $ 717,232 Animal Nutrition & Health 151,773 157,454 Specialty Products 182,092 190,449 Other and Unallocated (1) 107,481 100,708 Total $ 1,169,215 $ 1,165,843 Business Segment Net Sales Three Months Ended 2021 2020 Human Nutrition & Health $ 104,516 $ 95,508 Animal Nutrition & Health 51,148 48,641 Specialty Products 28,008 27,996 Other and Unallocated (2) 1,984 2,291 Total $ 185,656 $ 174,436 Business Segment Earnings Before Income Taxes Three Months Ended 2021 2020 Human Nutrition & Health $ 19,690 $ 12,135 Animal Nutrition & Health 5,056 8,044 Specialty Products 7,189 7,986 Other and Unallocated (2) (1,360) (1,887) Interest and other expense (592) (1,788) Total $ 29,983 $ 24,490 Depreciation/Amortization Three Months Ended 2021 2020 Human Nutrition & Health $ 7,573 $ 7,844 Animal Nutrition & Health 1,764 1,755 Specialty Products 2,269 2,392 Other and Unallocated (2) 758 558 Total $ 12,364 $ 12,549 Capital Expenditures Three Months Ended 2021 2020 Human Nutrition & Health $ 3,967 $ 3,507 Animal Nutrition & Health 1,631 1,092 Specialty Products 330 382 Other and Unallocated (2) 23 8 Total $ 5,951 $ 4,989 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $234 and $1,272 for the first quarter of 2021 and 2020, respectively, and (ii) Unallocated amortization expense of $675 and $472 for the first quarter of 2021 and 2020, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that was included in interest expense in Company's consolidated statement of earnings.

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenues	The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended 2021 2020 Product Sales $ 175,988 $ 167,565 Co-manufacturing 7,278 5,241 Consignment 1,051 619 Product Sales Revenue 184,317 173,425 Royalty Revenue 1,339 1,011 Total Revenue $ 185,656 $ 174,436 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended 2021 2020 United States $ 137,851 $ 126,909 Foreign Countries 47,805 47,527 Total Revenue $ 185,656 $ 174,436

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Cash paid during the three months ended March 31, 2021 and 2020 for income taxes and interest is as follows: Three Months Ended 2021 2020 Income taxes $ 2 $ 8 Interest $ 1,363 $ 1,619

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	3 Months Ended
	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive income/(loss) were as follows: Three Months Ended 2021 2020 Net foreign currency translation adjustment $ (6,143) $ 781 Net change of cash flow hedge (see Note 19 for further information) Unrealized gain (loss) on cash flow hedge 677 (3,933) Tax (165) 826 Net of tax 512 (3,107) Net change in postretirement benefit plan (see Note 14 for further information) Amortization of prior service cost 18 19 Amortization of gain (5) (13) Prior service credit (4) — Total before tax 9 6 Tax (2) (1) Adjustment (1) — (584) Net of tax and adjustment 7 (579) Total other comprehensive loss $ (5,624) $ (2,905) (1) One-time adjustment to the postretirement account.
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income (loss) at March 31, 2021 and December 31, 2020 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2020 $ 7,653 $ (3,684) $ 204 $ 4,173 Other comprehensive (loss) income (6,143) 512 7 (5,624) Balance March 31, 2021 $ 1,510 $ (3,172) $ 211 $ (1,451)

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	3 Months Ended
	Mar. 31, 2021
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Cost	Net periodic benefit costs for such retirement medical plans were as follows: Three Months Ended 2021 2020 Service cost $ 22 $ 17 Interest cost 6 6 Amortization of prior service cost 18 19 Amortization of gain (6) (13) Net periodic benefit cost $ 40 $ 29 Net periodic benefit costs for such benefit pension plans were as follows: Three Months Ended 2021 2020 Service cost with interest to end of year $ 17 $ 26 Interest cost 4 5 Expected return on plan assets (9) (4) Amortization of gain 1 — Total net periodic benefit cost $ 13 $ 27

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases	Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at March 31, 2021 are as follows: Year April 1, 2021 to December 31, 2021 $ 2,498 2022 2,557 2023 2,045 2024 1,238 2025 639 2026 443 Thereafter 2,241 Total minimum lease payments $ 11,661

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Summary of Right of Use Asset and Lease Liabilities	Right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 are summarized as follows: Right of use assets March 31, 2021 December 31, 2020 Operating leases $ 6,189 $ 5,838 Finance leases 2,519 2,572 Total $ 8,708 $ 8,410 Lease liabilities - current March 31, 2021 December 31, 2020 Operating leases $ 2,121 $ 2,178 Finance leases 161 159 Total $ 2,282 $ 2,337 Lease liabilities - non-current March 31, 2021 December 31, 2020 Operating leases $ 3,992 $ 3,607 Finance leases 2,431 2,472 Total $ 6,423 $ 6,079
Schedule of Lease Cost	For the three months ended March 31, 2021 and 2020, the Company's total lease costs were as follows, which included both amounts recognized in profits or losses during the periods and amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended 2021 2020 Lease Cost Operating lease cost $ 716 $ 741 Finance Lease cost Amortization of ROU asset 52 — Interest on lease liabilities 33 — Total finance lease cost $ 85 $ — Total lease cost $ 801 $ 741 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 739 $ 744 Operating cash flows from finance leases 33 — Financing cash flows from finance leases 39 — $ 811 $ 744 ROU assets obtained in exchange for new operating lease liabilities, net of ROU assets disposals $ 1,036 $ 9 Weighted-average remaining lease term - operating leases 4.14 years 4.93 years Weighted-average remaining lease term - finance leases 12.00 years n/a Weighted-average discount rate - operating leases 4.2 % 4.6 % Weighted-average discount rate - finance leases 5.1 % n/a

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	3 Months Ended
	Mar. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value of Derivative Instruments	As of March 31, 2021 and December 31, 2020, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative liabilities March 31, 2021 December 31, 2020 Interest rate swap $ 4,188 $ 4,865 Cross-currency swap 2,570 6,793 Derivative liabilities $ 6,758 $ 11,658
Schedule of Gains (Losses) on Hedging Instruments	Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three months ended March 31, 2021 and 2020: Location within Statements of Comprehensive Income Three Months Ended 2021 2020 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 512 $ (3,107) Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment 3,197 4,419 Total $ 3,709 $ 1,312

STOCKHOLDERS' EQUITY - Stock-Ba

STOCKHOLDERS' EQUITY - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Net earnings	$ (2,022)	$ (1,663)
Expiration period of options granted	10 years
Shares available for future awards (in shares)	688,727
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 299	266
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 2,323	$ 1,915
Minimum | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Minimum | Restricted Stock | Non-Employee Director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	3 years
Maximum | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	4 years
Maximum | Restricted Stock | Non-Employee Director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period	4 years

STOCKHOLDERS' EQUITY - Stock Op

STOCKHOLDERS' EQUITY - Stock Options (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	858	951
Granted (in shares)	129	145
Exercised (in shares)	(34)	(82)
Forfeited (in shares)	(2)	(4)
Canceled (in shares)	(1)	0
Outstanding at end of period (in shares)	950	1,010
Exercisable at end of period (in shares)	604	664
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 80.58	$ 68.18
Granted (in dollars per share)	119.11	111.94
Exercised (in dollars per share)	70.53	54.39
Forfeited (in dollars per share)	101.38	89.90
Canceled (in dollars per share)	74.57	0
Outstanding at end of period (in dollars per share)	86.11	75.48
Exercisable at end of period (in dollars per share)	$ 73.11	$ 65.39
Aggregate intrinsic value, outstanding, beginning of period	$ 29,735	$ 31,814
Aggregate intrinsic value, outstanding, end of period	37,322	25,399
Aggregate intrinsic value, exercisable, end of period	$ 31,603	$ 22,131
Weighted average remaining contractual term, outstanding	7 years	6 years 8 months 12 days
Weighted average remaining contractual term, exercisable	5 years 9 months 18 days	5 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield rate	0.50%	0.50%
Expected volatility rate	33.00%	26.00%
Risk-free interest rate	0.50%	1.40%
Expected term	4 years 10 months 24 days	3 years 8 months 12 days
Weighted-average fair value of options granted (in dollars per share)	$ 33.10	$ 23.05
Total intrinsic value of stock options exercised	$ 1,917	$ 4,019

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Unrecognized compensation cost	$ 23,009	$ 19,308
Period for unrecognized compensation cost to be recognized over	1 year 10 months 24 days
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Estimated share-based compensation expense			$ 11,400
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	159	138
Granted (in shares)	36	34
Vested (in shares)	(10)	(20)
Forfeited (in shares)	(2)	(1)
Non-vested balance as of end of period (in shares)	183	151
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 90.71	$ 80.03
Granted (in dollars per share)	119.11	111.44
Vested (in dollars per share)	85.37	67.43
Forfeited (in dollars per share)	86.69	86.82
Non-vested balance as of end of period (in dollars per share)	$ 96.70	$ 89.21
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	71	70
Granted (in shares)	36	20
Vested (in shares)	(24)	(8)
Forfeited (in shares)	(11)	(11)
Non-vested balance as of end of period (in shares)	72	71
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 91.99	$ 81.26
Granted (in dollars per share)	108.74	126.46
Vested (in dollars per share)	70.64	104.15
Forfeited (in dollars per share)	74.57	82.71
Non-vested balance as of end of period (in dollars per share)	$ 110.22	$ 91.99
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	0.20%	1.40%
Dividend yield rate	0.60%	0.50%
Expected volatility rate	33.00%	24.00%
Initial TSR	11.70%	10.90%
Cliff vest	100.00%

STOCKHOLDERS' EQUITY - Repurcha

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)	3,763,038
Aggregate number of shares repurchased since inception (in shares)	2,581,871
Number of shares remaining in treasury (in shares)	19,089		76,084
Number of shares acquired under stock repurchase plan and subsequently reissued (in shares)	13,475	8,224
Treasury stock acquired, average cost (in dollars per share)	$ 118.41	$ 108.40

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 28,900	$ 24,536
Work in progress	3,822	3,050
Finished goods	44,300	43,034
Total inventories	$ 77,022	$ 70,620

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 381,202	$ 378,212
Less: accumulated depreciation	154,689	150,116
Property, plant and equipment, net	226,513	228,096
Land
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	11,923	12,215
Building
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	87,677	86,873
Equipment
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	248,326	247,884
Construction in progress
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 33,276	$ 31,240

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 526,246,000		$ 529,463,000
Amortization of identifiable intangible assets	6,484,000	$ 6,979,000
Identifiable intangible assets with indefinite useful lives	0	$ 0
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	18,497,000
2022	23,044,000
2023	19,447,000
2024	10,611,000
2025	6,348,000
2026	$ 5,112,000

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 328,133	$ 330,063
Accumulated amortization	214,474	208,403
Customer relationships & lists
Identifiable intangible assets [Abstract]
Gross carrying amount	241,516	243,557
Accumulated amortization	$ 161,772	158,051
Customer relationships & lists | Minimum
Identifiable intangible assets [Abstract]
Amortization period	10 years
Customer relationships & lists | Maximum
Identifiable intangible assets [Abstract]
Amortization period	20 years
Trademarks & trade names
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 43,154	43,208
Accumulated amortization	$ 26,084	24,974
Trademarks & trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization period	2 years
Trademarks & trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization period	17 years
Developed technology
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 20,318	21,674
Accumulated amortization	$ 13,991	13,693
Developed technology | Minimum
Identifiable intangible assets [Abstract]
Amortization period	5 years
Developed technology | Maximum
Identifiable intangible assets [Abstract]
Amortization period	12 years
Other
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 23,145	21,624
Accumulated amortization	$ 12,627	$ 11,685
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization period	2 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization period	18 years

EQUITY-METHOD INVESTMENT (Detai

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)vote	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Equity Method Investment, Summarized Financial Information [Abstract]
Percentage of production offtake	66.66%
Percentage of operating expenses to be absorbed	66.66%
St. Gabriel CC Company, LLC
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	66.66%
Loss relating to joint venture's expenses	$ 144	$ 138
Capital contribution to investment	13	$ 667
Carrying value of joint venture	$ 4,840		$ 4,971
St. Gabriel CC Company, LLC | Eastman Chemical Company
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	33.34%
Number of votes | vote	2

REVOLVING LOAN (Details)

REVOLVING LOAN (Details) - USD ($)	Jun. 27, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Line of Credit Facility [Abstract]
Outstanding balance		$ 153,569,000		$ 163,569,000
Capitalized costs net of accumulated amortization		632,000		$ 703,000
Amortization expense pertaining to capitalized costs		$ 71,000	$ 71,000
Credit Agreement
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 500,000,000
Interest rate		1.234%
Commitment fee percentage		0.15%
Unused portion of revolving loan		$ 346,431,000
Credit Agreement | Minimum
Line of Credit Facility [Abstract]
Commitment fee percentage		0.15%
Credit Agreement | Maximum
Line of Credit Facility [Abstract]
Commitment fee percentage		0.275%
Term Loan
Line of Credit Facility [Abstract]
Maximum borrowing capacity	350,000,000
Payments for outstanding balance	210,750,000
Revolving Credit Facility
Line of Credit Facility [Abstract]
Maximum borrowing capacity	$ 100,000,000
Installment payments required		$ 0

NET EARNINGS PER SHARE (Details

NET EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share, Basic and Diluted [Abstract]
Net Earnings - Basic and Diluted	$ 23,411	$ 19,768
Weighted average common shares - basic (in shares)	32,255,000	32,135,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)	402,000	382,000
Weighted average common shares - diluted (in shares)	32,657,000	32,517,000
Net earnings per share - basic (in dollars per share)	$ 0.73	$ 0.62
Net earnings per share - diluted (in dollars per share)	$ 0.72	$ 0.61
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock options outstanding, excluded from diluted earnings per share calculation (in shares)	311,030	212,551

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate	21.90%	19.30%
Unrecognized tax benefits	$ 5,400		$ 5,335
Accrued interest and penalties related to unrecognized tax benefits	$ 1,908		$ 1,845

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
	Mar. 31, 2021numberOfReportableSegmentnumberOfFillingFacility
Segment Reporting [Abstract]
Number of business segments | numberOfReportableSegment	3
Number of filling facilities | numberOfFillingFacility	5

SEGMENT INFORMATION - Business

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Segment information [Abstract]
Assets	$ 1,169,215	$ 1,165,843
Other and Unallocated
Segment information [Abstract]
Assets	107,481	100,708
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Assets	727,869	717,232
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Assets	151,773	157,454
Specialty Products | Operating Segments
Segment information [Abstract]
Assets	$ 182,092	$ 190,449

SEGMENT INFORMATION - Busines_2

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment information [Abstract]
Net sales	$ 185,656	$ 174,436
Other and Unallocated
Segment information [Abstract]
Net sales	1,984	2,291
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Net sales	104,516	95,508
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Net sales	51,148	48,641
Specialty Products | Operating Segments
Segment information [Abstract]
Net sales	$ 28,008	$ 27,996

SEGMENT INFORMATION - Busines_3

SEGMENT INFORMATION - Business Segment Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment information [Abstract]
Earnings before income taxes	$ 29,983	$ 24,490
Interest and other (expense)	(592)	(1,788)
Other and Unallocated
Segment information [Abstract]
Earnings before income taxes	(1,360)	(1,887)
Interest and other expense
Segment information [Abstract]
Interest and other (expense)	(592)	(1,788)
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Earnings before income taxes	19,690	12,135
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Earnings before income taxes	5,056	8,044
Specialty Products | Operating Segments
Segment information [Abstract]
Earnings before income taxes	$ 7,189	$ 7,986

SEGMENT INFORMATION - Depreciat

SEGMENT INFORMATION - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment information [Abstract]
Depreciation and amortization	$ 12,364	$ 12,549
Other and Unallocated
Segment information [Abstract]
Depreciation and amortization	758	558
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Depreciation and amortization	7,573	7,844
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Depreciation and amortization	1,764	1,755
Specialty Products | Operating Segments
Segment information [Abstract]
Depreciation and amortization	$ 2,269	$ 2,392

SEGMENT INFORMATION - Capital E

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment information [Abstract]
Capital expenditures	$ 5,951	$ 4,989
Amortization of identifiable intangible assets	6,484	6,979
Other and Unallocated
Segment information [Abstract]
Capital expenditures	23	8
Transaction and integration related costs	234	1,272
Amortization of identifiable intangible assets	675	472
Human Nutrition & Health | Operating Segments
Segment information [Abstract]
Capital expenditures	3,967	3,507
Animal Nutrition & Health | Operating Segments
Segment information [Abstract]
Capital expenditures	1,631	1,092
Specialty Products | Operating Segments
Segment information [Abstract]
Capital expenditures	$ 330	$ 382

REVENUE - Schedule of Disaggreg

REVENUE - Schedule of Disaggregation of Revenues (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)numberOfRevenueSubstream	Mar. 31, 2020USD ($)
Revenue [Abstract]
Net sales	$ 185,656	$ 174,436
United States
Revenue [Abstract]
Net sales	137,851	126,909
Foreign Countries
Revenue [Abstract]
Net sales	47,805	47,527
Product Sales
Revenue [Abstract]
Net sales	175,988	167,565
Co-manufacturing
Revenue [Abstract]
Net sales	7,278	5,241
Consignment
Revenue [Abstract]
Net sales	1,051	619
Product Sales Revenue
Revenue [Abstract]
Net sales	$ 184,317	173,425
Number of sub-streams of revenue | numberOfRevenueSubstream	4
Royalty Revenue
Revenue [Abstract]
Net sales	$ 1,339	$ 1,011

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 2	$ 8
Interest	$ 1,363	$ 1,619

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Changes in accumulated other comprehensive income (loss) [Abstract]
Net foreign currency translation adjustment	$ (6,143)	$ 781
Unrealized gain (loss) on cash flow hedge	677	(3,933)
Tax	(165)	826
Net of tax	512	(3,107)
Net change in postretirement benefit plan (see Note 14 for further information)
Amortization of prior service cost	18	19
Amortization of gain	(5)	(13)
Prior service credit	(4)	0
Total before tax	9	6
Tax	(2)	(1)
Adjustment	0	(584)
Net of tax and adjustment	7	(579)
Other comprehensive loss	(5,624)	(2,905)
Tax (expense) benefit on net investment hedge	$ (1,026)	$ (1,174)

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 828,233	$ 743,667
Other comprehensive (loss) income	(5,624)	(2,905)
Ending balance	849,492	766,271
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	7,653
Other comprehensive (loss) income	(6,143)
Ending balance	1,510
Cash flow hedge
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3,684)
Other comprehensive (loss) income	512
Ending balance	(3,172)
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	204
Other comprehensive (loss) income	7
Ending balance	211
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	4,173	(5,564)
Other comprehensive (loss) income	(5,624)	(2,905)
Ending balance	$ (1,451)	$ (8,469)

EMPLOYEE BENEFIT PLANS (Details

EMPLOYEE BENEFIT PLANS (Details) $ in Thousands	Jan. 01, 2021numberOfPlan	Mar. 31, 2021USD ($)numberOfPlan	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)numberOfPlan
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | numberOfPlan	1			2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost		$ 22	$ 17
Interest cost		6	6
Amortization of prior service cost		18	19
Amortization of gain		(6)	(13)
Net periodic benefit cost		40	29
Benefit obligation		1,402		$ 1,374
Deferred compensation liability		5,420		3,581
Related rabbi trust assets		5,319		3,581
Maximum
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Historical cash payments for retirement medical plan claims per year		$ 100
Postretirement Medical Plan
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit plans | numberOfPlan		2
Defined Benefit Pension Plan | Chemogas Defined Pension Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost		$ 17	26
Interest cost		4	5
Expected return on plan assets		(9)	(4)
Amortization of gain		1	0
Net periodic benefit cost		13	$ 27
Benefit obligation		$ 920		$ 950

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Mar. 31, 2021USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
April 1, 2021 to December 31, 2021	$ 2,498
2022	2,557
2023	2,045
2024	1,238
2025	639
2026	443
Thereafter	2,241
Total minimum lease payments	$ 11,661

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)numberOfFinancialInstrument	Dec. 31, 2020USD ($)
Fair value of financial instruments [Abstract]
Number of financial instruments held for trading purposes | numberOfFinancialInstrument	0
Related rabbi trust assets	$ 5,319	$ 3,581
Derivative liabilities	(6,758)	(11,658)
Derivative Financial Instruments, Liabilities | Cross-currency swap
Fair value of financial instruments [Abstract]
Derivative liabilities	(2,570)	(6,793)
Derivative Financial Instruments, Liabilities | Interest rate swap
Fair value of financial instruments [Abstract]
Derivative liabilities	(4,188)	(4,865)
Money Market Funds | Level 1
Fair value of financial instruments [Abstract]
Cash and cash equivalents	$ 813	$ 817

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Related party transactions [Abstract]
Finished goods received from related party recorded in cost of goods sold	$ 4,391	$ 3,721
Receivable from related party	3,794		$ 2,809
Payables to related parties	2,569		2,239
Related party receivable related to non-contractual monies	97		72
Related party payable related to non-contractual monies	296		$ 296
Services Provided
Related party transactions [Abstract]
Revenue from related party	827	853
Raw Materials Sold
Related party transactions [Abstract]
Revenue from related party	$ 5,462	$ 4,711

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)vote	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Number of tranches | vote	4
Finance lease liability	$ 2,592		$ 2,631
Rent expense charged to operations under lease agreements	$ 716	$ 741
Lessee, Operating Lease, Tranche One
Lessee, Lease, Description [Line Items]
Discount rate	1.45%
Lessee, Operating Lease, Tranche One | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	1 year
Lessee, Operating Lease, Tranche One | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	2 years
Lessee, Operating Lease, Tranche Two
Lessee, Lease, Description [Line Items]
Discount rate	2.04%
Lessee, Operating Lease, Tranche Two | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	3 years
Lessee, Operating Lease, Tranche Two | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	4 years
Lessee, Operating Lease, Tranche Three
Lessee, Lease, Description [Line Items]
Discount rate	2.38%
Lessee, Operating Lease, Tranche Three | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	5 years
Lessee, Operating Lease, Tranche Three | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	9 years
Lessee, Operating Lease, Tranche Four
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	10 years
Discount rate	3.10%

LEASES - Right-of-Use Assets an

LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Assets and Liabilities, Lessee [Abstract]
Operating Lease - ROU	$ 6,189	$ 5,838
Finance Leases - ROU	2,519	2,572
Total right-of-use assets	8,708	8,410
Operating leases liabilities - current	2,121	2,178
Finance leases liabilities - current	161	159
Total lease liabilities, current	2,282	2,337
Operating leases liabilities - non-current	3,992	3,607
Finance leases liabilities - non-current	2,431	2,472
Total lease liabilities, non-current	$ 6,423	$ 6,079

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Lease Cost
Operating lease cost	$ 716	$ 741
Amortization of ROU asset	52	0
Interest on lease liabilities	33	0
Total finance lease cost	85	0
Total lease cost	801	741
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	739	744
Operating cash flows from finance leases	33	0
Financing cash flows from finance leases	39	0
Cash flows from operating and finance leases	811	744
ROU assets obtained in exchange for new operating lease liabilities, net of ROU assets disposals	$ 1,036	$ 9
Weighted-average remaining lease term - operating leases	4 years 1 month 20 days	4 years 11 months 4 days
Weighted-average remaining lease term - finance leases	12 years
Weighted-average discount rate - operating leases	4.20%	4.60%
Weighted-average discount rate - finance leases	5.10%

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	May 28, 2019
Interest Expense | Interest rate swap
Derivative [Line Items]
Net interest income (expense)	$ (521)	$ (121)
Designated as Hedging Instrument | Interest rate swap
Derivative [Line Items]
Notional amount of derivatives			$ 108,569
Designated as Hedging Instrument | Interest rate swap | Pay-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate			2.05%
Designated as Hedging Instrument | Cross-currency swap
Derivative [Line Items]
Notional amount of derivatives			$ 108,569
Designated as Hedging Instrument | Cross-currency swap | Pay-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate			0.00%
Designated as Hedging Instrument | Cross-currency swap | Receive-Fixed Interest Rate
Derivative [Line Items]
Fixed interest rate			2.05%
Designated as Hedging Instrument | Interest Expense | Cross-currency swap
Derivative [Line Items]
Net interest income (expense)	$ 556	$ 563

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Interest rate swap
Derivative Liability [Abstract]
Derivative liabilities	$ 4,188	$ 4,865
Cross-currency swap
Derivative Liability [Abstract]
Derivative liabilities	2,570	6,793
Derivative Financial Instruments, Liabilities
Derivative Liability [Abstract]
Derivative liabilities	$ 6,758	$ 11,658

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Gains and losses from hedging instruments recognized in AOCI	$ 3,709	$ 1,312
Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedge (interest rate swap), net of tax	512	(3,107)
Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	$ 3,197	$ 4,419